Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Some providers who manage both transitions between GLP-1 medications and transitions from traditional appetite suppressants to GLP-1 therapy report that patients who understand the transition timeline and set appropriate expectations have much better adherence and outcomes than those who expect immediate equivalence between the two medication types
The FDA concludes that more information is needed to determine potential harm
Ted The doctor was very informative of all aspects of the medication that I am now taking
Shkel O, Kharkivska Y, Kim YK, Lee JS
We encourage you to think about your health as a long-term investment
In the SURMOUNT-1 trial, also published in NEJM, participants receiving tirzepatide achieved weight reductions ranging from 16.0% to 22.5% depending on dose over 72 weeks
